This topic contains a solution. Click here to go to the answer

Author Question: Response prevention prevents the client from engaging in _____ behaviors. a. anxiety reducing b. ... (Read 62 times)

KWilfred

  • Hero Member
  • *****
  • Posts: 570
Response prevention prevents the client from engaging in _____ behaviors.
 
  a. anxiety reducing
  b. adaptive avoidance
  c. covert escape
  d. emotive-retaliation

Question 2

An alternate procedure often included in flooding is
 
  a. in vivo desensitization.
  b. an anxiety hierarchy.
  c. a competing response.
  d. response prevention.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

kkenney

  • Sr. Member
  • ****
  • Posts: 352
Answer to Question 1

a

Answer to Question 2

d




KWilfred

  • Member
  • Posts: 570
Reply 2 on: Jun 22, 2018
Great answer, keep it coming :)


bdobbins

  • Member
  • Posts: 326
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

Though “Krazy Glue” or “Super Glue” has the ability to seal small wounds, it is not recommended for this purpose since it contains many substances that should not enter the body through the skin, and may be harmful.

Did you know?

Asthma-like symptoms were first recorded about 3,500 years ago in Egypt. The first manuscript specifically written about asthma was in the year 1190, describing a condition characterized by sudden breathlessness. The treatments listed in this manuscript include chicken soup, herbs, and sexual abstinence.

Did you know?

No drugs are available to relieve parathyroid disease. Parathyroid disease is caused by a parathyroid tumor, and it needs to be removed by surgery.

Did you know?

Prostaglandins were first isolated from human semen in Sweden in the 1930s. They were so named because the researcher thought that they came from the prostate gland. In fact, prostaglandins exist and are synthesized in almost every cell of the body.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library